Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 42 Article 2
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 21, Issue 42, 20 October 2016
Systematic Review
Mertz, Fadel, Lam, Tran, Srigley, Asner, Science, Kuster, Nemeth, Johnstone, Ortiz, and Loeb: Herd effect from influenza vaccination in non-healthcare settings: a systematic review of randomised controlled trials and observational studies

+ Author affiliations


Citation style for this article: Mertz D, Fadel SA, Lam P, Tran D, Srigley JA, Asner SA, Science M, Kuster SP, Nemeth J, Johnstone J, Ortiz JR, Loeb M. Herd effect from influenza vaccination in non-healthcare settings: a systematic review of randomised controlled trials and observational studies. Euro Surveill. 2016;21(42):pii=30378. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.42.30378

Received:21 October 2015; Accepted:23 April 2016


Introduction

Influenza is a major cause of morbidity and mortality worldwide [1-3]. Many countries recommend vaccination against influenza to prevent influenza infections, in particular for groups at high risk for complications [4-7]. Some high risk groups, such as young children and elderly persons (commonly defined as those above 65 years of age), experience decreased influenza vaccine effectiveness compared with healthy adults [8,9], complicating influenza prevention strategies. Moreover, because such groups represent a minority of the population at large, the population-wide impact of vaccination of risk groups may be limited [7,10].

Influenza vaccine modelling and ecological studies identifying benefits of herd effect have informed seasonal and pandemic influenza vaccine policies [10,11], herd effect being usually defined as the indirect protection of individuals susceptible to infection when a sufficient proportion of the population is immune to the pathogen. Vaccinating persons most likely to respond to the influenza vaccine and relying on herd effect to reduce the chance of exposure to influenza may protect unvaccinated or high-risk individuals. Herd effect may therefore mitigate the consequences of impaired vaccine response in some high-risk groups [12-14].

The purpose of this systematic review was to summarise the evidence on herd effect from influenza vaccination outside healthcare settings. These data may help to inform public health on influenza vaccine research and policy development.

Methods

All decisions regarding eligibility criteria, search strategy, study selection, assessment of risk for bias, explanation for heterogeneity, data collection and analysis were established before data collection. The protocol was registered with the international prospective register of systematic reviews (PROSPERO) [15] (CRD42014009401) and was reported in accordance with the PRISMA statement [16].

Eligibility criteria and outcomes assessed

Studies assessing the protective effect of influenza vaccination vs no influenza vaccination (either no vaccination, placebo or alternative vaccine) on contacts of any age group in a non-healthcare setting were eligible. The definition of contacts was broad and included anyone in the same community, school or household. Study designs included randomised controlled trials (RCTs) and observational studies with a non-influenza vaccine comparator group. For the latter study type, quasi-experimental (before–after) studies, cohort studies, case–control studies and cross-sectional studies were eligible. Ecological studies and modelling studies were excluded. We also excluded studies conducted within healthcare institutions, such as nursing homes and hospitals, and studies in languages other than English.

The primary outcome was influenza in non-vaccinated contacts exposed to persons vaccinated against influenza vs those not vaccinated. Influenza included both laboratory-confirmed influenza (defined by one or more of the following: nucleic acid amplification testing, viral culture, antigen detection, pre-/post-season or acute/convalescent serology) or non-laboratory-defined evidence. Non-laboratory-defined evidence required the presence of influenza-like illness (ILI, as per the study definition) within a period of time when laboratory-confirmed influenza was circulating in the study area. Secondary outcomes included hospitalisation, pneumonia and death.

Search strategy, study selection and data extraction

We searched MEDLINE (since 1950), EMBASE (since 1980), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (since 1982), Global Health (since 1973) and the Cochrane Central Register of Controlled Trials (CENTRAL) up to 7 March 2014. We also searched reference lists of identified articles and those of review articles for eligible studies.

Multiple teams of two reviewers independently screened titles and abstracts and, for studies identified by at least one reviewer to be of potential interest, full-text articles were screened. Data from eligible studies were extracted independently by two reviewers using a database. Any disagreement between the reviewers was resolved by consensus or arbitration by a third reviewer. We attempted to contact the first and corresponding author of the original article whenever potentially important information was missing.

Assessment of the risk of bias and of the overall quality of evidence was also conducted by two reviewers independently. We used the Cochrane Review Collaboration’s tool [17] to assess the risk of bias for RCTs, and the Newcastle-Ottawa scale (NOS) [18] to assess the quality of observational studies. The overall quality of evidence was assessed using the grading of recommendations assessment, development and evaluation (GRADE) criteria [19]. Given the small number of studies, no formal assessment of the risk of publication bias could be conducted [20].

Data analysis

We performed meta-analyses of RCTs and observational studies separately. We calculated odds ratios (ORs) and corresponding 95% confidence intervals (CIs) as summary estimates using random-effects modelling (using RevMan 5.3 [21]).

We planned a priori to conduct two subgroup analyses. First, we examined herd effect by study setting, comparing the effect in household studies, school-based studies (where the impact on non-vaccinated schoolchildren was measured) and community studies. For community studies, those comparing geographically defined areas with different vaccination strategies were considered. We hypothesised that the closer the contact was to vaccinated persons, the stronger the effect would be. Second, we assessed whether the herd effect of the vaccination in young children (up to 5 years of age) was different from that in older children and teenagers (5–18 years), and in adults.

Heterogeneity was evaluated using χ2 and I2 statistics [22]. We considered a χ2 of < 0.10 or an I2 statistic of > 50% to reflect significant heterogeneity. If significant heterogeneity was found, we planned to perform additional subgroup analyses. Our a priori hypotheses to explain heterogeneity beyond the planned subgroup analyses were: laboratory-confirmed vs non-laboratory-confirmed influenza cases, and cases confirmed by nucleic acid amplification testing and viral culture vs cases confirmed by other laboratory methods. We also analysed the predominant circulating type/subtype (influenza A(H3N2) orA(H1N1), and influenza B).

Results

After removing 18,157 duplicates, we screened a total of 43,082 titles and abstracts, reviewed 184 full-text articles and included nine RCTs and four observational studies in our systematic review (Figure 1). Of the 13 RCTs and observational studies, seven were conducted in North America, and two each in Italy and Russia, and one in Malaysia and Hong Kong Special Administrative Region, respectively (Table 1).

Figure 1

Flowchart of included and excluded randomised control trials and observational studies identified in a systematic review of herd effect from influenza vaccination in non-healthcare settings

/images/dynamic/articles/22622/15-00591-f1

a Two randomised control trials did not report all numerator and denominator data and therefore could not be included in the meta-analysis.

Table 1

Study characteristics of studies included in a systematic review of herd effect arising from influenza vaccination in non-healthcare settings


First author [source] Study location Study period Predominant influenza virus type or subtype Intervention group Setting Number of vaccinees Number of contactsa Laboratory confirmation of influenza
Randomised control trials
Gruber [29] United States 1985/86 B Children aged 3–18 years Household 133 123 Yes
Clover [33] United States 1986/87 A(H1N1) Children aged 3–19 years Household 194 177 Yes
Rudenkob [23] Russia 1989–91 A(H3N2) Children aged 7–14 years School 11,071 Not available No
Hurwitz [13] United States 1996/97 Influenza B Children aged 2–5 years Household 127 228 No
Esposito [34] Italy 2000/01 H1N1 Children aged 0.5–9 years Household 127 349 No
Principib [24] Italy 2001/02 Influenza B Children aged 0.5–5 years Household 303 1,098 No
Hui [31] Malaysia 2005 Not reported Adults aged 18–64 years Household 346 362 No
Cowling [30] Hong Kong SAR 2008/09 A(H3N2) Children aged 6–15 years Household 119 312 Yes
Loeb [12] Canada 2009 A(H3N2) Children aged 1.5–15 years Community 947 2,326 Yes
Observational studies (all cohort studies)
Piedra [26] United States 1998–2001 A(H3N2) Children aged 1.5–18 years Community ca 40,000 350,296 No
Ghendon [25] Russia 2001–03 A(H3N2) Children aged 3–17 years Community 87,221 158,451 No
King [14] United States 2004/05 A(H3N2) Children aged 5–14 years Household 2,717 3,022c No
Kjos [27] United States 2010/11 A(H3N2) Children, age unavailable Elementary school
(5–10 year-olds)
1,012 937 No

  SAR: Special Administrative Region.

a The definition of contacts was broad and included anyone in the same community, school or household.

b The randomised control trial did not report all numerator and denominator data and therefore could not be included in the meta-analysis.

c In this study, the number of contacts was not reported. The number shown is the number of households (3,022) included in the analysis in intervention schools; there were 5,488 households in control schools).

Findings from randomised controlled trials

Of the nine RCTs included, seven were conducted in a household setting, one in a school and one in a community setting (Table 1). The intervention group consisted of children in all but one study. The total sample size of contacts was 4,975, with one study –the largest– not reporting the total number of contacts [23].

A total of six RCTs provided data for the primary analysis comparing influenza-like illness in contacts of vaccinated vs unvaccinated persons (Figure 2). Overall, no statistically significant herd effect was found (OR: 0.62; 95% CI: 0.34–1.12), with significant statistical heterogeneity (I2 = 78%). Only one study, by Loeb et al., assessed contacts for influenza virus infection at community level: vaccination of children reduced the influenza infection rate for the community (OR: 0.39; 95% CI: 0.26–0.57) [12]. In contrast, there was no statistically significant effect in the subgroup of RCTs assessing household contacts (OR: 0.71; 95% CI: 0.34–1.50). No other differences between subgroups were found (p = 0.15 for subgroup differences). There was an 86% reduction in the odds of 5–17 year-old contacts of vaccinated individuals becoming infected as compared with contacts of unvaccinated individuals (OR: 0.14; 95% CI: 0.03–0.70), while no statistically significant differences were found when contacts were less than five years-old or adults. This difference across age groups was not statistically significant (p = 0.26).

Figure 2

Meta-analysis of seven included randomised controlled trials reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated individuals in non-healthcare settings

/images/dynamic/articles/22622/15-00591-f2

CI: confidence interval; df: degrees of freedom; M-H: Mantel-Haenszel.

Given the significant amount of statistical heterogeneity in the primary analyses, we conducted additional subgroup analyses. Subgrouping by whether or not influenza was laboratory confirmed did not significantly reduce statistical heterogeneity (p for subgroup differences was 0.06; I2 = 70·8%), with a significant effect on influenza infections in contacts in RCTs with no laboratory confirmation (OR: 0.33; 95% CI: 0.17–0.64; I2 = 43%; n = 2) and no effect in RCTs using laboratory confirmation (OR: 0.87; 95% CI: 0.40–1.89; I2 = 81%; n = 4). Subgrouping by type of laboratory confirmation or by influenza virus type/subtype could not further explain the statistical heterogeneity.

Two RCTs provided data on hospitalisation of contacts, with no statistically significant difference seen (OR 0.83; 95% CI: 0.17–4.1). Only the RCT by Loeb et al. [12] reported on mortality and pneumonia in contacts, with no effect of the vaccine on either of these outcomes in community contacts. Because of the limited number of studies reporting these outcomes, no subgroup analyses could be performed.

Two other RCTs demonstrated a herd effect of influenza vaccination, but the data provided in the publications did not report the numerators and denominators needed for our meta-analysis, and we were unable to obtain further data or information from the authors. Principi et al. concluded that influenza vaccination significantly reduced the direct and indirect influenza-related costs in healthy children and their unvaccinated family members [24]. Rudenko et al. found that the use of a live attenuated influenza vaccine was associated with a lower rate of influenza-like illness in school staff and non-vaccinated children when comparing schools that had vs schools that did not have an institutional influenza vaccination programme [23].

Findings from observational studies

A total of four observational studies were identified (Table 1). The intervention groups consisted of children in all the studies. Two studies were conducted in a community setting, and one each in the household and school setting. The total sample size of contacts was more than 500,000. The level of analysis was the household, and not the individual person, in one of the studies [14].

Meta-analysis showed a significant reduction of influenza illness in contacts of vaccinated patients (OR 0.57; 95% CI: 0.43–0.77) (Figure 3). Heterogeneity was very high (I2 = 98%); however, the direction of the effect was identical in all studies, only the amount of the effect size varied across studies. No age-specific data were available. When comparing the three study settings, no significant subgroup effect was found (p = 0.85 for subgroup differences). Given that all studies were lacking laboratory confirmation, and all were conducted during influenza A(H3N2)-predominant influenza seasons, no further subgroup analyses could be performed.

Figure 3

Meta-analysis of four included observational studies reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated patients in non-healthcare settings

/images/dynamic/articles/22622/15-00591-f3

CI: confidence interval; df: degrees of freedom; M-H: Mantel-Haenszel.

Only Ghendon et al. [25] reported on pneumonia, and found a significant reduction in contacts of influenza vaccinated patients (OR: 0.38; 95% CI: 0.30–0.50). Hospital admission was only reported in one study [14]; showing higher hospital admission rates in contacts of vaccinated persons (OR: 1.92; 95% CI: 1.17–3.14). There were no studies reporting on mortality endpoints.

Risk of bias and grading of evidence

The most common potential risks of bias in the included RCTs were lack of appropriate generation of the randomisation sequence, lack of allocation concealment and lack of blinding of patients and healthcare providers (Table 2). The RCTs scored a mean of 4.3 (range: 2–7) when assessed against seven domains.

Table 2

Risk of bias in nine included randomised controlled trials reporting on influenza infections in contacts of influenza vaccinated vs unvaccinated individuals in non-healthcare settings


First author [source] Risk of bias
Sequence generation Allocation concealment Blinding of patients Blinding of healthcare provider Blinding of outcome adjudicators Incomplete data addressed Selective reporting
Gruber [29] NK NK Low Low Low Low Low
Clover [33] NK NK Low NK Low Low Low
Rudenko [23] NK NK Low NK Low Low Low
Hurwitz [13] NK NK Low NK NK NK Low
Esposito [34] Low NK Low Low Low Low Low
Principi [24] NK NK High High NK Low Low
Hui [31] NK NK High High Low Low Low
Cowling [30] Low NK  Low  Low Low Low Low
Loeb [12] Low Low Low Low Low Low Low
Percentage low risk of biasa 33 11 22 33 78 89 100

NK: not known, as either unclear or not reported.

a The percentage low risk of bias for each domain was calculated by dividing the number of randomised controlled trials (RCTs) at low risk of bias by the total number of RCTs (n = 9).

The observational studies were awarded a mean of 6.25 points of a maximum of nine on the Newcastle-Ottawa scale, i.e. they were in a middle range of risk of bias (7 for Piedra et al. [26] and Ghendon et al. [25], 6 for Kjos [27] and 5 for King et al. [14]).

Applying GRADE criteria, we decreased the level of evidence for the primary outcome because of serious limitations in the quality of the studies (i.e. risk of bias in RCTs and observational design in non-RCTs) and inconsistency with significant statistical heterogeneity. Therefore, the overall level of evidence supporting a herd effect of influenza vaccines in preventing influenza virus infection in contacts in non-healthcare settings was considered to be low.

Discussion

We found an overall low level of evidence supporting an indirect or herd effect of influenza vaccination in preventing influenza virus infection in vaccinated persons’ contacts. In all but one study we identified, children were vaccinated. While observational studies showed a significant effect, the summary estimates from RCTs did not show a statistically significant effect. Few data were available on herd effect of influenza vaccination preventing hospital admission, pneumonia and death.

Point estimates of four of the six RCTs that reported on the prevention of influenza virus infection in contacts of vaccinated persons pointed towards a potential benefit of vaccination, but no significant effect was found overall. In an RCT by Loeb et al. involving Hutterite communities [12], vaccination of children in an enclosed community significantly reduced influenza infections in contacts. The uptake of influenza vaccination in that RCT, which had a low risk of bias in all domains assessed, was ca 83%. The RCT confirmed the findings from an observational study by Monto et al. that found a similar effect at the population level by vaccinating schoolchildren in one community in Michigan, United States [28]. However, no strong evidence was found in a household setting [29,30]. A possible explanation is that vaccinating only one child per household, as done in the study by Cowling et al., may have been insufficient to have a measurable effect [30]. In the study by Gruber et al., in contrast, all children three years of age and older received the vaccine, but again there was no effect on household contacts. However, the study was limited by the low attack rate and was therefore likely underpowered [29]. Furthermore, the authors argued that the non-vaccinated contacts were likely to be immune to the predominant influenza B strain that circulated in previous years. It is therefore unclear what key factors are needed to achieve a herd effect in the household, particularly given the importance of the broader community as a potential source of infection of the non-vaccinated. Notably, the only study that investigated herd effect of influenza vaccination of adults did find a statistically significant effect [31]. However, this study had significant methodological limitations, including lack of blinding. It should be acknowledged that two studies that both reported a significant herd effect of influenza vaccination could not be included in the meta-analysis because of the lack of detail reported in the published article, and no additional information could be obtained from the authors [23,24].

In contrast to our findings from RCTs, we found evidence of herd effect following influenza vaccination in observational studies, which was corroborated by a recent observational study by Pannaraj et al., who found that unvaccinated children may be protected in schools with vaccination rates approaching 50% [32].

Our extensive screening of over 40,000 studies found very few studies that were designed to measure herd effects of influenza vaccination. One reason for this may be the cost of community influenza surveillance as well as the cost of clinical trials. While modelling studies demonstrate that herd immunity can be achieved by vaccinating young children [10], we are surprised by how few studies with laboratory-confirmed influenza as an outcome support the modelling literature. Moreover, there are very limited data available to estimate herd effect of influenza vaccination programmes. As indirect benefits would increase the cost-effectiveness of these programmes, such data would be highly valuable for vaccine advisory bodies and decision makers evaluating whether to initiate or expand influenza vaccine programmes.

Our review highlights the need for more rigorous studies using laboratory-confirmed influenza virus infections as an outcome. Data on a herd effect on outcomes other than influenza virus infection were sparse, due either to outcomes not being measured or to inadequate power to detect a difference. Although the effect of influenza vaccination on mortality has been demonstrated through modelling [10], high-quality studies would better support the ability of influenza vaccination to prevent hospital admissions, pneumonia or death in contacts through herd effect.

Strengths of this systematic review include a systematic, protocol-driven and comprehensive review with extensive literature search strategy including RCTs and observational studies. In addition, rigorous assessment of eligibility ensured high reliability of the results. All subgroup analyses were defined a priori. A rigorous use of the GRADE approach ensured a transparent and comprehensive approach to evaluate overall quality of the studies. An important limitation, however, was the presence of statistically significant heterogeneity that could not be explained by a priori defined subgroup analyses. We assume that differences in study designs and clinical heterogeneity in terms of study population, outcome assessment and health service resources may have resulted in differences in outcomes that could not be explained by the intervention per se. Furthermore, differences in vaccine effectiveness in case of mismatch and existing immunity if the circulating strain had been dominant for several seasons may have introduced heterogeneity across the included studies. Another major limitation was the potential risk of bias in the majority of studies, which further decreased the level of evidence. Finally, all but one study vaccinated children, thus, no generalisation to vaccination programmes in adults can be made, and the evidence is too limited to conclude in what setting(s) a significant herd effect may or may not be achieved.

In summary, herd effects are assumed with influenza vaccine programmes, but there are few studies that quantify the herd effect of vaccination. We found low-level evidence supporting a herd effect of vaccination on influenza virus infection in contacts of vaccinated persons. Further rigorous studies are needed in order to better understand under which circumstances vaccination may prevent influenza and its complications in contacts.


Acknowledgements

This work was funded by a grant from the World Health Organization. JRO is a staff member of the World Health Organization. The author alone is responsible for the views expressed in this publication, which do not necessarily represent the decisions, policy or views of the World Health Organization.

DM is a recipient of a Research Early Career Award from Hamilton Health Sciences Foundation (Jack Hirsh Fellowship). The authors would like to acknowledge the contributions of the United States Centers for Disease Control and Prevention (CDC), which provides financial support to the World Health Organization Initiative for Vaccine Research (U50 CK000431).

Conflict of interest

SPK received travel grants from Pfizer and Novartis. DT received grant funding from GSK Canada. SAF, PL, JS, SAA, MS, JN, JJ, JRO, DM, ML: none declared.

Authors’ contributions

Conception and design (DM, JRO, ML), data acquisition (SAF, PL, DT, JS, SAA, MS, SPK, JN, JJ), interpretation of data (DM, JRO, ML), drafting the manuscript (DM, ML), revising manuscript for important intellectual content (SAF, PL, DT, JS, SAA, MS, SPK, JN, JJ, JRO). All authors gave final approval of the version to be published and agreed to be accountable for all aspects of the work.


References

  1. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY,  et al.  Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-95. DOI: 10.1016/S1473-3099(12)70121-4 PMID: 22738893

  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V,  et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. DOI: 10.1016/S0140-6736(12)61728-0 PMID: 23245604

  3. Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA,  et al.  Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet. 2011;378(9807):1917-30. DOI: 10.1016/S0140-6736(11)61051-9 PMID: 22078723

  4. Centers for Disease Control and Prevention (CDC). People at High Risk of Developing Flu-Related Complications. Atlanta, GA: CDC. [Accessed 21 Oct 2015]. Available from: http://www.cdc.gov/flu/index.htm

  5. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA,  et al. , Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.MMWR Recomm Rep. 2010;59(RR-8):1-62.PMID: 20689501

  6. Strategic Advisory Group of Experts on Immunization - report of the extraordinary meeting on the influenza A (H1N1) 2009 pandemic, 7 July 2009. Wkly Epidemiol Rec. 2009;84(30):301-4.PMID: 19630186

  7. World Health Organization (WHO). SAGE meeting of April 2012. Geneva: WHO. [Accessed 21 Oct 2015]. Available from: http://www.who.int/influenza/vaccines/SAGE_information/en/index.html

  8. Agarwal S, Busse PJ. Innate and adaptive immunosenescence.Ann Allergy Asthma Immunol. 2010;104(3):183-90, quiz 190-2, 210. DOI: 10.1016/j.anai.2009.11.009 PMID: 20377107

  9. Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system.J Leukoc Biol. 2010;87(6):1001-9. DOI: 10.1189/jlb.0809542 PMID: 20200405

  10. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza.N Engl J Med. 2001;344(12):889-96. DOI: 10.1056/NEJM200103223441204 PMID: 11259722

  11. Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.Am J Epidemiol. 2009;170(6):679-86. DOI: 10.1093/aje/kwp237 PMID: 19679750

  12. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ,  et al.  Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303(10):943-50. DOI: 10.1001/jama.2010.250 PMID: 20215608

  13. Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M,  et al.  Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA. 2000;284(13):1677-82. DOI: 10.1001/jama.284.13.1677 PMID: 11015798

  14. King JC, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E,  et al.  Effectiveness of school-based influenza vaccination. N Engl J Med. 2006;355(24):2523-32. DOI: 10.1056/NEJMoa055414 PMID: 17167135

  15. Centre for Reviews and Dissemination. University of York. PROSPERO. International prospective register of systematic reviews. York: Centre for Reviews and Dissemination, University of York. [Accessed 5 Oct 2016]. Available from: http://www.crd.york.ac.uk/PROSPERO/

  16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP,  et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-34. DOI: 10.1016/j.jclinepi.2009.06.006 PMID: 19631507

  17. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). London: The Cochrane Collaboration; 2011. Available from: http://handbook.cochrane.org

  18. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute. [Accessed 21 Oct 2015]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

  19. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S,  et al.  Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. DOI: 10.1136/bmj.328.7454.1490 PMID: 15205295

  20. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J,  et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343(jul22 1):d4002. DOI: 10.1136/bmj.d4002 PMID: 21784880

  21. Cochrane Informatics and Knowledge Management Department. RevMan 5 download and installation. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. [Accessed 5 Oct 2016]. Available from: http://tech.cochrane.org/revman/download

  22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses.BMJ. 2003;327(7414):557-60. DOI: 10.1136/bmj.327.7414.557 PMID: 12958120

  23. Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP,  et al.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 1993;168(4):881-7. DOI: 10.1093/infdis/168.4.881 PMID: 8376833

  24. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families.Pediatr Infect Dis J. 2003;22(10) Suppl;S207-10. DOI: 10.1097/01.inf.0000092188.48726.e4 PMID: 14551476

  25. Ghendon YZ, Kaira AN, Elshina GA. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly.Epidemiol Infect. 2006;134(1):71-8. DOI: 10.1017/S0950268805005650 PMID: 16316494

  26. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler G, Riggs M, Griffith M,  et al.  Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine. 2005;23(13):1540-8. DOI: 10.1016/j.vaccine.2004.09.025 PMID: 15694506

  27. Kjos SA, Irving SA, Meece JK, Belongia EA. Elementary school-based influenza vaccination: evaluating impact on respiratory illness absenteeism and laboratory-confirmed influenza.PLoS One. 2013;8(8):e72243. DOI: 10.1371/journal.pone.0072243 PMID: 23991071

  28. Monto AS, Davenport FM, Napier JA, Francis T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren.J Infect Dis. 1970;122(1):16-25. DOI: 10.1093/infdis/122.1-2.16 PMID: 5433709

  29. Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW,  et al.  Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child. 1990;144(5):595-600.PMID: 2330929

  30. Cowling BJ, Ng S, Ma ESK, Fang VJ, So HC, Wai W,  et al.  Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis. 2012;55(5):695-702. DOI: 10.1093/cid/cis518 PMID: 22670050

  31. Hui LS, Rashwan H, bin Jaafar MH, Hussaini HM, Isahak DI. Effectiveness of influenza vaccine in preventing influenza-like illness among faculty of dentistry staff and students in Universiti Kebangsaan Malaysia.Healthc Infect. 2008;13(1):4-9 .DOI: 10.1071/HI08003

  32. Pannaraj PS, Wang HL, Rivas H, Wiryawan H, Smit M, Green N,  et al.  School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. Clin Infect Dis. 2014;59(3):325-32. DOI: 10.1093/cid/ciu340 PMID: 24829215

  33. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses.J Infect Dis. 1991;163(2):300-4. DOI: 10.1093/infdis/163.2.300 PMID: 1988512

  34. Esposito S, Marchisio P, Cavagna R, Gironi S, Bosis S, Lambertini L,  et al.  Effectiveness of influenza vaccination of children with recurrent respiratory tract infections in reducing respiratory-related morbidity within the households. Vaccine. 2003;21(23):3162-8. DOI: 10.1016/S0264-410X(03)00253-6 PMID: 12804844



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.